• 1. 四川大學(xué)華西醫(yī)院老年科,成都,6100412. 四川大學(xué)華西醫(yī)院循證醫(yī)學(xué)與臨床流行病學(xué)中心,成都,610041;

針對進(jìn)展期前列腺癌的治療問題,運(yùn)用循證醫(yī)學(xué)的方法全面檢索相關(guān)的臨床治療證據(jù)并進(jìn)行質(zhì)量評價.結(jié)果顯示,各種雄激素阻斷方法療效相似,但早期進(jìn)行雄激素全阻斷的療效更好;對激素不敏感性前列腺癌,采用米托蒽醌、強(qiáng)的松、多西他賽及蘇拉明等化療藥物有一定療效;鍶-89內(nèi)照射的鎮(zhèn)痛效果較傳統(tǒng)的外照射好,而雙磷酸鹽無效;抗雄激素撤退可使部分患者前列腺特異性抗原下降,但臨床療效有待進(jìn)一步評價.

引用本文： 王 慧,董碧蓉. 1例進(jìn)展期前列腺癌的循證治療. 中國循證醫(yī)學(xué)雜志, 2005, 05(5): 415-418. doi: 復(fù)制

1. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality[J]. Urology, 2000; 55(3):328-332.
2. Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer(Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
3. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer(Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
4. Muthuramalingam SR, Patel K, Protheroe A. Management of patients with hormone refractory prostate cancer[J]. Clin Oncol,2004;16(8):505-516.
5. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJCM. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade[J]. Journal of Urology,1997;15(5):1731-1735.
6. Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer[J]? Br J Cancer, 2004; 91(6):1005-1011.
7. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer[J]. Journal of Clinical Oncology, 1994; 12(4): 689-694.
8. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study[J]. Journal of Clinical Oncology,1999; 17(8): 2506-2513.
9. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004; 351(15): 1502-1512.
10. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B 99813. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813[J]. Cancer, 2003; 98(12): 2592-2598.
11. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480[J]. Journal of Clinical Oncology, 2002; 20(16): 3369-3375.
12. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin ther apy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone[J]. Journal of Clinical Oncology, 2000; 18(7): 1440-1450.
13. Roque M, Martinez MJ, Alonso-Coello P, Catala E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
14. Roque M, Martinez MJ, Alonso-Coello P, Catala E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
15. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial[J]. Journal of Nuclear Medicine, 2002; 43(1): 76-89.
16. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
17. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer[J]. Journal of Clinical Oncology,2003; 21(23): 4277-4284.
18. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK, Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)[J]. Journal of the National Cancer Institute, 2003; 95(17): 1300-1311.
19. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain[J]. Journal of Clinical Oncology, 2003; 21(17): 3335-3342.
  1. 1. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality[J]. Urology, 2000; 55(3):328-332.
  2. 2. Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer(Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  3. 3. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer(Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  4. 4. Muthuramalingam SR, Patel K, Protheroe A. Management of patients with hormone refractory prostate cancer[J]. Clin Oncol,2004;16(8):505-516.
  5. 5. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJCM. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade[J]. Journal of Urology,1997;15(5):1731-1735.
  6. 6. Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer[J]? Br J Cancer, 2004; 91(6):1005-1011.
  7. 7. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer[J]. Journal of Clinical Oncology, 1994; 12(4): 689-694.
  8. 8. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study[J]. Journal of Clinical Oncology,1999; 17(8): 2506-2513.
  9. 9. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004; 351(15): 1502-1512.
  10. 10. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B 99813. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813[J]. Cancer, 2003; 98(12): 2592-2598.
  11. 11. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480[J]. Journal of Clinical Oncology, 2002; 20(16): 3369-3375.
  12. 12. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin ther apy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone[J]. Journal of Clinical Oncology, 2000; 18(7): 1440-1450.
  13. 13. Roque M, Martinez MJ, Alonso-Coello P, Catala E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  14. 14. Roque M, Martinez MJ, Alonso-Coello P, Catala E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  15. 15. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial[J]. Journal of Nuclear Medicine, 2002; 43(1): 76-89.
  16. 16. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases (Cochrane review)[M/CD]. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  17. 17. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer[J]. Journal of Clinical Oncology,2003; 21(23): 4277-4284.
  18. 18. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK, Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)[J]. Journal of the National Cancer Institute, 2003; 95(17): 1300-1311.
  19. 19. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain[J]. Journal of Clinical Oncology, 2003; 21(17): 3335-3342.